The success of CS1-CD28/CD3ζ-NK92 cells in restricting the growth of MM, enhancing IFN-γ production and improving the survival rate (132) has encouraged oncologists to design CAR-NK immunotherapies against solid tumors. The gene discussed is IFNG; the disease is Miyoshi myopathy.